SM
LPCN icon

Sabby Management’s Lipocine LPCN Stock Holding History

Sabby Management’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-55
Closed -$133K – 132
2020
Q3 		$133K Buy
+55
New +$1.46K 0.02% 111
2016
Q2 		– Sell
-21
Closed -$355K – 315
2016
Q1 		$355K Hold
21
– – 0.02% 235
2015
Q4 		$453K Buy
+21
New +$4.41K 0.02% 243

Other funds holding LPCN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sabby Management's LPCN Position: Q4 2020 in Review

Sabby Management sold out of Lipocine (LPCN) in Q4 2020, closing a stake of 26,086 shares — an estimated $625K sold.

Sabby Management first reported a position in LPCN in Q2 2014 and held it in 9 quarters. The position peaked at $6.22M in Q2 2015. 33 funds tracked by Wall St. Rank hold LPCN as of Q4 2020.

  • Sabby Management reported no remaining Lipocine position as of Q4 2020 after selling out during the quarter.
  • Sabby Management sold 26,086 Lipocine shares in Q4 2020, an estimated $625K.
  • Sabby Management first reported a position in Lipocine in Q2 2014 and held it in 9 quarters.
  • Sabby Management's Lipocine position peaked at $6.22M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Lipocine as of Q4 2020.

Based on Sabby Management's 13F filing for Q4 2020, filed 16 Feb 2021.